Last reviewed · How we verify
Besifloxacin Ophthalmic
At a glance
| Generic name | Besifloxacin Ophthalmic |
|---|---|
| Also known as | Besivance ophthalmic suspension 0.6% |
| Sponsor | Instituto de Oftalmología Fundación Conde de Valenciana |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Besifloxacin in Bacterial Keratitis (NA)
- Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification (PHASE4)
- A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery (PHASE4)
- Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (PHASE3)
- Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery (PHASE1)
- Study of Ocular Penetration of Topically Administered Fluoroquinolones (PHASE4)
- Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children (PHASE1)
- A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: